PROPANC BIOPHARMA INC
PPCBNASDAQTrading Snapshot
- Day Range
- $0.52 – $0.53
- 52-Week Range
- $0.52 – $52.50
- Volume
- $1.90B
- Avg Volume
- $2.24B
- Shares Outstanding
- 2.3M
- Next Earnings
- Oct 29, 2026
Fundamentals Snapshot
- Annual Revenue
- $193,848
- Last Q Revenue
- $53,534
- P/E Ratio
- -0.0
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-5.70
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +100000.1%
Why Investors Own PPCB
- ✓High-growth profile — revenue up +2.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 75% gross margin and 13% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
PROPANC BIOPHARMA INC
PPCB
StockOtter · stockotter.spaceAbout PROPANC BIOPHARMA INC
Propanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on pancreatic, ovarian, and colorectal malignancies. The company's leading therapeutic candidate, PRP, is a unique formulation currently in the preclinical stage of development. This product is designed to enhance the effectiveness of multiple enzymes that work together to combat cancer. Propanc Biopharma is also engaged in a collaborative research effort with the University of Jaén, initiating the POP1 joint drug discovery program. Founded in 2007, the entity was originally known as Propanc Health Group Corporation before officially changing its name to Propanc Biopharma, Inc. in April 2017. The company's headquarters are located in Camberwell, Australia.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results
"The Company is poised to capitalize on the foundation set
Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015
New Preclinical PDAC Package for PRP Shows >90% Tumor-Growth Inhibition & >2.5-Fold Survival Benefit; Company Contrasts Mechanism, Breadth, & Development Role Against Erasca's Phase 1 ERAS-0015 Dataset MELBOURNE, Austral
Propanc Biopharma Positions PRP's EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.
MELBOURNE, Australia, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, inclu
Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027
MELBOURNE, Australia, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, inclu
Revolution Medicines' Pancreatic Cancer Drug Approval Validates Microcap Propanc Biopharma's Breakthrough Survival Results
Propanc Biopharma Inc. (NASDAQ:PPCB) stock surged on Thursday after compelling preclinical and early translational data for its primary drug candidate, PRP, focused on treating pancreatic ductal adenocarcinoma.
Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit
MELBOURNE, Australia, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, includ